{"entity":{"id":"doc1021","kind":"drug","name":"DOC1021","aka":[],"tldr":"DOC1021 is a cancer vaccine from Diakonos Oncology Corporation, in registered phase 2 trials for glioma & glioblastoma, melanoma.","summary":"DOC1021 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by Diakonos Oncology Corporation, in glioma & glioblastoma, melanoma. A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of DOC1021","url":"https://clinicaltrials.gov/search?intr=DOC1021"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["glioblastoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["diakonos-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06805305","nct07288112"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"DOC1021","modality":"Cancer vaccine","mechanism":"A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/doc1021/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"company":[{"id":"diakonos-oncology","kind":"company","name":"Diakonos Oncology","route":"/companies/diakonos-oncology/"}],"trial":[{"id":"nct07288112","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","route":"/trials/nct07288112/"},{"id":"nct06805305","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","route":"/trials/nct06805305/"}]}}